## VCYT: Veracyte, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.78 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($39.43)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 22 ($4.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 16.5% (+68.9%)
- Vanguard Group Inc: 10.8% (+5.0%)
- Artisan Partners Lim: 9.3% (+16.6%)
- FMR, LLC: 8.6% (-16.2%)
- ARK Investment Manag: 5.7% (+17.5%)

### Key Risks

1. High beta (1.83) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Insider selling cluster: $4.9M in recent transactions.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.78 indicates undervaluation relative to growth. Balance sheet: strong liquidity (6.2x), low leverage (D/E 0.09). Insider selling cluster ($4.9M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.4B |
| Beta | 1.83 |
| 52W Range | $22.61 - $50.71 |
| Short Interest | 7.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.78 |
| Forward P/E | 26.4 |
| Current P/E | 25.8 |
| YoY Growth | -2.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -4.5% to -1.2% (+3.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.30x) but short-term weakness (below SMA20). RSI neutral at 48. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.25% (CS: 25) | Neutral |
| RSI_14 | 47.9 | Neutral |
| MACD Histogram | -0.27 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 1.013x | Above |
| vs SMA200 | 1.297x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $42.39
- **Stop Loss:** $39.43 (7.0% risk)
- **Target:** $48.31 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 486
- **Position Value:** $20,601.54
- **Portfolio %:** 20.60%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-24 (Est: $0.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.32 | $0.51 | +59.5% |
| 2025Q2 | $0.30 | $0.44 | +48.5% |
| 2025Q1 | $0.20 | $0.31 | +51.3% |
| 2024Q4 | $0.26 | $0.36 | +40.0% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*